| Risk of breast cancer according to the status of HER-2/neu oncogene amplification. | breast, |
| Quantification of HER2 oncoprotein in fine-needle aspirates of the breast. | breast, |
| The clinical pattern of HER-2/neu oncogene overexpressing breast cancer in Pakistani patients at initial presentation: an analysis of HER-2/neu positive versus negative disease--a preliminary report. | breast, |
| Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells. | bladder, |
| Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. | breast, |
| c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. | HNSC, |
| [P185 (Neu) oncoprotein in the prognosis of bladder carcinoma. Experience of 5 years]. | bladder, |
| c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast. | breast, |
| Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients. | breast, |
| Correlation between histological grade and c-erbB2 oncoprotein overexpression in infiltrating ductal carcinoma of breast. | breast, |
| C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. | breast, |
| Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. | breast, |
| Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients. | breast, |
| Serum c-erb B2 oncoprotein levels are elevated in recurrent and metastatic breast cancer. | breast, |
| C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa. | gastric, |
| [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors]. | breast, |
| Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. | breast,ovarian, |
| Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. | breast, |
| Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma. | breast, |
| K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. | pancreatic, |